Fracture healing: Mechanisms and interventions

Nature Reviews Rheumatology

Volumn 11, Issue 1, 2015, Pages 45-54

  Einhorn, Thomas A ^a   Gerstenfeld, Louis C ^b  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; PARATHYROID HORMONE; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT OSTEOGENIC PROTEIN 1; RECOMBINANT PLATELET DERIVED GROWTH FACTOR BB; WNT PROTEIN;

ADAPTIVE IMMUNITY; BIOLOGICAL FUNCTIONS; BIOSYNTHESIS; BONE MARROW TRANSPLANTATION; BONE REGENERATION; BONE REMODELING; CATABOLISM; DRUG MEGADOSE; ECHOGRAPHY; ELECTROMAGNETIC FIELD; ENVIRONMENTAL FACTOR; FEMUR FRACTURE; FRACTURE FIXATION; FRACTURE HEALING; FRACTURE IMMOBILIZATION; HUMAN; INNATE IMMUNITY; LOW DRUG DOSE; LOW INTENSITY PULSED ULTRASONOGRAPHY; MUSCULOSKELETAL FUNCTION; NONHUMAN; ONTOGENY; PELVIS FRACTURE; PRIORITY JOURNAL; REVIEW; STEM CELL; TIBIA FRACTURE; WNT SIGNALING PATHWAY; ANIMAL; FRACTURES, BONE; PATHOLOGY; PHYSIOLOGY;

ANIMALS; BONE REGENERATION; FRACTURE HEALING; FRACTURES, BONE; HUMANS;

EID: 84925503883     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2014.164     Document Type: Review

References (101)

1. Bolander, M. E. Regulation of fracture repair by growth factors. Proc. Soc. Exp. Biol. Med. 200, 165-170 (1992).
2. Einhorn, T. A. The cell and molecular biology of fracture healing. Clin. Orthop. Relat. Res. 355 (Suppl.), S7-S21 (1998).
3. Ferguson, C., Alpern, E., Miclau, T. & Helms, J. A. Does adult fracture repair recapitulate embryonic skeletal formation? Mech. Dev. 87, 57-66 (1999).
4. Gerstenfeld, L. C., Cullinane, D. M., Barnes, G. L., Graves, D. T. & Einhorn, T. A. Fracture healing as a post-natal developmental process: molecular, spatial, and temporal aspects of its regulation. J. Cell Biochem. 88, 873-884 (2003).
5. Vortkamp, A. et al. Recapitulation of signals regulating embryonic bone formation during postnatal growth and in fracture repair. Mech. Dev. 71, 65-76 (1998).
6. Bais, M. et al. Transcriptional analysis of fracture healing and the induction of embryonic stem cell-related genes. PLoS ONE 4, e5393 (2009).
7. Phillips, A. M. Overview of the fracture healing cascade. Injury 36 (Suppl. 3), 55-57 (2005).
8. Buckwalter, J. A., Einhorn, T. A., Bolander, M. E. & Cruess, R. L. in Rockwood and Green's Fractures in Adults (Bucholz, R. W. & Heckman, J. D.) 245-271 (Lippincott, Williams and Wilkins, 2001).
9. Hausman, M. R., Schaffler, M. B. & Majeska, R. J. Prevention of fracture healing in rats by an inhibitor of angiogenesis. Bone 29, 560-564 (2001).
10. Kurdy, N. M., Weiss, J. B. & Bate, A. Endothelial stimulating angiogenic factor in early fracture healing. Injury 27, 143-145 (1996).
11. Young, L. F., Choi, Y. W., Behrens, F. F., DeFouw, D. O. & Einhorn, T. A. Programmed removal of chondrocytes during endochondral fracture healing. J. Orthop. Res. 6, 144-149 (1998).
12. Gerstenfeld, L. C. et al. Impaired fracture healing in the absence of TNF-α signaling: the role of TNF-α in endochondral cartilage resorption. J. Bone Miner. Res. 18, 1584-1592 (2003).
13. Melnyk, M., Henke, T., Claes, L. & Augat, P. Revascularisation during fracture healing with soft tissue injury. Arch. Orthop. Trauma Surg. 128, 1159-1165 (2008).
14. Holstein, J. H. et al. Endostatin inhibits callus remodeling during fracture healing in mice. J. Orthop. Res. 31, 1579-1584 (2013).
15. Kon, T. et al. Expression of osteoprotegerin, receptor activator of NF-κB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing. J. Bone Miner. Res. 16, 1004-1014 (2001).
16. Ozaki, A., Tsunoda, M., Kinoshita, S. & Saura, R. Role of fracture hematoma and periosteum during fracture healing in rats: interaction of fracture hematoma and the periosteum in the initial step of the healing process. J. Orthop. Sci. 5, 64-70 (2005).
17. Timlin, M. D. et al. Fracture hematoma is a potent proinflammatory mediator of neutrophil function. J. Trauma 58, 1223-1229 (2005).
18. Meert, K. L., Ofenstein, J. P. & Sarnaik, A. P. Altered T cell cytokine production following mechanical trauma. Ann. Clin. Lab. Sci. 28, 283-288 (1998).
19. REG cells in fracture healing as characterized in the Fas-deficient (lpr) mouse model of lupus. J. Bone Miner. Res. 29, 1478-1491 (2014).
20. Nauta, A. J. & Fibbe, W. E. Immunomodulatory properties of mesenchymal stromal cells. Blood 110, 3499-3506 (2007).
21. Noël, D., Djouad, F., Bouffi, C., Mrugala, D. & Jorgensen, C. Multipotent mesenchymal stromal cells and immune tolerance. Leuk. Lymphoma 48, 1283-1289 (2007).
22. Rizzo, R. et al. A functional role for soluble HLA-G. antigens in immune modulation mediated by mesenchymal stromal cells. Cytotherapy 10, 364-375 (2008).
23. Morandi, F. et al. Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens. Stem Cells 26, 1275-1287 (2008).
24. Montespan, F., Deschaseaux, F., Sensébé, L., Carosella, E. D., Rouas-Freiss, N. Osteodifferentiated mesenchymal stem cells from bone marrow and adipose tissue express HLA-G. and display immunomodulatory properties in HLA-mismatched settings: implications in bone repair therapy. J. Immunol. Res. 2014, 23034 (2014).
25. Najar, M. et al. Immune-related antigens, surface molecules and regulatory factors in human-derived mesenchymal stromal cells: the expression and impact of inflammatory priming. Stem Cell Rev. 8, 1188-1198 (2012).
26. Uccelli, A., Pistoia, V. & Moretta, L. Mesenchymal stem cells: a new strategy for immunosuppression? Trends Immunol. 28, 219-226 (2007).
27. Yang, X. et al. Callus mineralization and maturation are delayed during fracture healing in interleukin-6 knockout mice. Bone 41, 928-936 (2007).
28. Wallace, A., Cooney, T. E., Englund, R. & Lubahn, J. D. Effects of interleukin-6 ablation on fracture healing in mice. J. Orthop. Res. 29, 1437-1442 (2011).
29. Nam, D. et al. T-lymphocytes enable osteoblast maturation via IL-17F during the early phase of fracture repair. PLoS ONE 7, e40044 (2012).
30. Glass, G. E. et al. TNF-α promotes fracture repair by augmenting the recruitment and differentiation of muscle-derived stromal cells. Proc. Natl Acad. Sci. USA 108, 1585-1590 (2011).
31. Motsitsi, N. S. Management of infected nonunion of long bones: the last decade (1996-2006). Injury 39, 55-60 (2007).
32. Alblowi, J. et al. High levels of tumor necrosis factor-α contribute to accelerated loss of cartilage in diabetic fracture healing. Am. J. Pathol. 175, 1574-1585 (2009).
33. Kayal, J. et al. TNF-α mediates diabetes enhanced chondrocyte apoptosis during fracture healing and stimulates chondrocyte apoptosis through FOXO-1. J. Bone Miner. Res. 25, 1604-1615 (2010).
34. Claes, L., Recknagel, S. & Ignatius, A. Fracture healing under healthy and inflammatory conditions. Nat. Rev. Rheumatol. 8, 133-143 (2012).
35. Santavirta, S. et al. Immunologic studies of nonunited fractures. Acta Orthop. Scand. 63, 579-586 (1992).
36. Askalonov, A. A. Changes in some indices of cellular immunity in patients with uncomplicated and complicated healing of bone fractures. J. Hyg. Epidemiol. Microbiol. Immunol. 25, 307-310 (1991).
37. Askalonov, A. A., Gordienko, S. M., Avdyunicheva, O. E., Bondarenko, A. V. & Voronkov, S. F. The role of T system immunity in reparatory regeneration of the bone tissue in animals. J. Hyg. Epidemiol. Microbiol. Immunol. 31, 219-224 (1987).
38. Hauser, C. J. et al. The immune microenvironment of human fracture/soft-tissue hematomas and its relationship to systemic immunity. J. Trauma 42, 895-903 (1997).
39. Toben, D. et al. Fracture healing is accelerated in the absence of the adaptive immune system. J. Bone Miner. Res. 26, 113-124 (2011).
40. Born, W. K., Reardon, C. L. & O'Brien, R. L. The function of γδ T cells in innate immunity. Curr. Opin. Immunol. 18, 31-38 (2006).
41. Colburn, N. T., Zaal, K. J., Wang, F. & Tuan, R. A role for gamma delta T-cells in a mouse model of fracture healing. Arthritis Rheum. 60, 1694-1703 (2009).
42. Melief, S. M. et al. Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward anti-inflammatory macrophages. Stem Cells 31, 1980-1991 (2013).
43. Yan, Z., Zhuansun, Y., Chen, R., Li, J. & Ran, P. Immunomodulation of mesenchymal stromal cells on regulatory T cells and its possible mechanism. Exp. Cell Res. 15, 65-74 (2014).
44. Utvåg, S. E., Grundnes, O., Rindal, D. B. & Reikerås, O. Influence of extensive muscle injury on fracture healing in rat tibia. J. Orthop. Trauma 17, 430-435 (2003).
45. Claes, L. et al. The effect of both a thoracic trauma and a soft-tissue trauma on fracture healing in a rat model. Acta Orthop. 82, 223-227 (2011).
46. Gardner, T. N., Stoll, T., Marks, L., Mishra, S. & Knothe Tate, M. The influence of mechanical stimulus on the pattern of tissue differentiation in a long bone fracture - an FEM study. J. Biomech. 33, 415-425 (2000).
47. Claes, L. E. & Heigele, C. A. Magnitudes of local stress and strain along bony surfaces predict the course and type of fracture healing. J. Biomech. 32, 255-266 (1999).
48. Morgan, E. F. et al. Correlations between local strains and tissue phenotypes in an experimental model of skeletal healing. J. Biomech. 43, 2418-2424 (2010).
49. Colnot, C. Skeletal cell fate decisions within periosteum and bone marrow during bone regeneration. J. Bone Miner. Res. 24, 274-282 (2009).
50. Yu, Y. Y., Lieu, S., Lu, C. & Colnot, C. Bone morphogenetic protein 2 stimulates endochondral ossification by regulating periosteal cell fate during bone repair. Bone 47, 65-73 (2010).
51. Liu, R. et al. Myogenic progenitors contribute to open but not closed fracture repair. BMC Musculoskelet. Disord. 12, 288 (2011).
52. Olerud, S. & Strömberg, L. Intramedullary reaming and nailing: its early effects on cortical bone vascularization. Orthopedics 9, 1204-1208 (1986).
53. McCarthy, I. D. & Hughes, S. P. The vascular response to fracture micromovement. Clin. Orthop. Relat. Res. 301, 281-290 (1994).
54. Claes, L., Eckert-Hübner, K. & Augat, P. The effect of mechanical stability on local vascularization and tissue differentiation in callus healing. J. Orthop. Res. 20, 1099-1105 (2002).
55. Axelrad, T. W. & Einhorn, T. A. Bone morphogenetic proteins in orthopaedic surgery. Cytokine Growth Factor Rev. 20, 481-488 (2009).
56. Khosla, S., Westendorf, J. J. & Oursler, M. J. Building bone to reverse osteoporosis and repair fractures. J. Clin. Invest. 118, 421-428 (2008).
57. Du, X., Xie, Y., Xian, C. J. & Chen, L. Role of FGFs/FGFRs in skeletal development and bone regeneration. J. Cell Physiol. 227, 3731-3734 (2012).
58. Fei, Y., Gronowicz, G. & Hurley, M. M. Fibroblast growth factor-2, bone homeostasis and fracture repair. Curr. Pharm. Des. 19, 3354-3363 (2013).
59. Edwards, P. C. et al. Sonic hedgehog gene-enhanced tissue engineering for bone regeneration. Gene Ther. 12, 75-86 (2005).
60. Song, K., Rao, N. J., Chen, M. L., Huang, Z. J. & Cao, Y. G. Enhanced bone regeneration with sequential delivery of basic fibroblast growth factor and sonic hedgehog. Injury 42, 796-802 (2011).
61. Barnes, G. L. et al. Stimulation of fracture-healing with systemic intermittent parathyroid hormone treatment. J. Bone Joint Surg. Am. 90 (Suppl. 1), 120-127 (2008).
62. Jørgensen, N. R. & Schwarz, P. Effects of anti-osteoporosis medications on fracture healing. Curr. Osteoporos. Rep. 9, 149-145 (2011).
63. Patil, A. S., Sable, R. B. & Kothari, R. M. An update on transforming growth factor-β (TGF-β): sources, types, functions and clinical applicability for cartilage/bone healing. J. Cell. Physiol. 226, 3094-3103 (2011).
64. Virk, M. S. et al. Systemic administration of sclerostin antibody enhances bone repair in a critical-sized femoral defect in a rat model. J. Bone Joint Surg. Am. 95, 694-701 (2013).
65. Ke, H. Z., Richards, W. G. Li, X. & Ominsky, M. S. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr. Rev. 33, 747-783 (2012).
66. Kamiya, N. The role of BMPs in bone anabolism and their potential targets SOST and DKK1. Curr. Mol. Pharmacol. 5, 153-163 (2012).
67. Kakar, S. et al. Enhanced chondrogenesis and Wnt signaling in PTH treated fractures. J. Bone Miner. Res. 22, 1903-1912 (2007).
68. Baron, R. & Kneissel, M. Wnt signaling in bone homeostasis and disease: from human mutations to treatments. Nat. Med. 19, 179-192 (2013).
69. Fei, Y. & Hurley, M. M. Role of fibroblast growth factor 2 and Wnt signaling in anabolic effects of parathyroid hormone on bone formation. J. Cell. Physiol. 227, 3539-3545 (2012).
70. Alkhiary, Y. M. et al. Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). J. Bone Joint Surg. Am. 87, 731-741 (2005).
71. Yasuda, I. Fundamental aspects of fracture treatment. J. Kyoto Med. Soc. 4, 395-406 (1953).
72. Brighton, C. T. et al. A multicenter study of the treatment of non-union with constant direct current. J. Bone Joint Surg. Am. 63, 2-13 (1981).
73. Brighton, C. T. Current concepts review. The treatment of non-unions with electricity. J. Bone Joint Surg. Am. 63, 847-851 (1981).
74. Scott, G. & King, J. B. A prospective, double-blind trial of electrical capacitive coupling in the treatment of non-union of long bones. J. Bone Joint Surg. Am. 76, 820-826 (1994).
75. Sharrard, W. J. A double-blind trial of pulsed electromagnetic fields for delayed union of tibial fractures. J. Bone Joint Surg. Am. 72, 347-355 (1990).
76. Mollon, B., da Silva, V., Busse, J. W., Einhorn, T. A. & Bhandari, M. Electrical stimulation for long-bone fracture-healing: a meta-analysis of randomized controlled trials. J. Bone Joint Surg. Am. 90, 2322-2330 (2008).
77. Heckman, J., Ryaby, J. McCabe, J., Frey, J. J. & Kilcoyne, R. F. Acceleration of tibial fracture-healing by non-invasive, low-intensity pulsed ultrasound. J. Bone Joint Surg. Am. 76, 26-34 (1994).
78. Kristiansen, T. K. The effect of low power specifically programmed ultrasound on the healing time of fresh fractures using a Colles' model. J. Orthop. Trauma 4, 227-228 (1990).
79. Busse, J. W. et al. Low intensity pulsed ultrasonography for fractures: systematic review of randomized controlled trials. BMJ 338, 351-360 (2009).
80. Wright, J. G., Einhorn, T. A. & Heckman, J. D. Grades of recommendation . J. Bone Joint Surg. Am. 87, 1909-1910, (2005).
81. Hernigou, P. Poignard, A., Beaujean, F. & Rouard, H. Percutaneous autologous bone-marrow grafting for nonunions. Influence of the number and concentration of progenitor cells. J. Bone Joint Surg. Am. 87, 1430-1437 (2005).
82. Kawaguchi, H. et al. A local application of recombinant human fibroblast growth factor 2 for tibial shaft fractures: a randomized, placebo-controlled trial. J. Bone Miner. Res. 12, 2735-2743 (2010).
83. DiGiovanni, C. W. et al. Recombinant human platelet-derived growth factor-BB and β-tricalcium phosphate (rhPDGF-BB/ β-TCP): an alternative to autogenous bone graft. North American Ortrhopedic Foot and Ankle Study Group. J. Bone Joint Surg. Am. 95, 1184-1192 (2013).
84. Friedlaender, G. E. et al. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatement of tibial nonunions. J. Bone Joint Surg. Am. 83 (Suppl. 1), S151-S158 (2001).
85. Blue Cross & Blue Shield of Mississippi. Bone morphogenetic protein [online], http://www.bcbsms.com/com/bcbsms/apps/ policysearch/views/viewpolicy.php?&noprint=yes&path=%2Fpolicy%2Femed%2Fbone-morphogenetic-protein.html (2014).
86. Govender, S. et al. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. BMP-2 Evaluation in Surgery for Tibial Trauma (BESTT) study group. J. Bone Joint Surg. Am. 84, 2123-2134 (2002).
87. Lyon, T. et al. Efficacy and safety of recombinant human bone morphogenetic protein-2/calcium phosphate matrix for closed tibial diaphyseal fracture: a double-blind, randomized, controlled phase I-II/III trial. J. Bone Joint Surg. Am. 95, 2088-2096 (2013).
88. Aro, H. T. et al. Recombinant human bone morphogenetic protein-2: a randomized trial in open tibial fractures treated with reamed nail fixation. J. Bone Joint Surg. Am. 93, 801-808 (2011).
89. Simmonds, M. C. et al. Safety and effectiveness of recombinant human bone morphogenetic protein-2 for spinal fusion: a meta-analysis of individual-participant data. Ann. Intern. Med. 158, 877-879 (2013).
90. Aspenberg, P. et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J. Bone Miner. Res. 24, 404-414 (2010).
91. Peichl, P., Holzer, L. A., Maier, R. & Holzer, G. Parathyroid hormone 1-84 accelerates fracture - healing in pubic bones of elderly osteoporotic women. J. Bone Joint Surg. Am. 93, 1583-1587 (2011).
92. Canalis, E., Giustina, A. & Bilezikian, J. P. Mechanisms of anabolic therapies for osteoporosis. N. Engl. J. Med. 357, 905-916 (2007).
93. Boyden, L. M. et al. High bone density due to a mutation in LDL-receptor-related protein 5. N. Engl. J. Med. 346, 1513-1521 (2002).
94. Staehling-Hampton, K. et al. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am. J. Med. Genet. 110, 144-152 (2002).
95. Hamersma, H., Gardner, J. & Beighton, P. The natural history of sclerosteosis. Clin. Genet. 63, 192-197 (2003).
96. Agholme, F., Li, X. Isaksson, H., Ke, H. Z. & Aspenberg, P. Sclerostin antibody treatment enhances metaphyseal bone healing in rats. J. Bone Miner. Res. 24, 2412-2418 (2012).
97. McDonald, M. M. et al. Inhibition of sclerostin by systemic treatment with sclerostin antibody enhances healing of proximal tibial defects in ovariectromized rats. J. Orthop. Res. 30, 1541-1548 (2012).
98. Sarahrudi, K., Thomas, A., Albrecht, C. & Aharinejad, S. Strongly enhanced levels of sclerostin during human fracture healing. J. Orthop. Res. 30, 1549-1155 (2012).
99. McClung, M. R. Romosozumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 370, 412-420 (2014).
100. Takahata, M., Schwarz, E. M., Chen, T., O'Keefe, R. J. & Awad, H. A. Delayed short-course treatment with teriparatide (PTH(1-34)) improves femoral allograft healing by enhancing intramembranous bone formation at the graft-host junction. J. Bone Miner. Res. 27, 26-37 (2012).
101. Morgan, E. F. et al. Combined effects of recombinant human BMP-7 (rhBMP-7) and parathyroid hormone (1-34) in metaphyseal bone healing. Bone 43, 1031-1038 (2008).